Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.250
-0.230-4.20%
Volume:72.16M
Turnover:381.46M
Market Cap:98.09B
PE:34.60
High:5.480
Open:5.480
Low:5.235
Close:5.480
52wk High:8.647
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.82
T/O Rate:0.39%
Dividend:0.12
Dividend Rate:2.29%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.58
PE(LYR):34.60
PS:2.49

Loading ...

Sino Biopharma Wins China NMPA Approval for First-Line Squamous NSCLC Combo Therapy

Reuters
·
Aug 07

Sino Biopharmaceutical - Nmpa Approves Benmelstobart with Chemotherapy Followed by Anlotinib for First-Line Sq-Nsclc

THOMSON REUTERS
·
Aug 07

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 07

Movement Alert|SBP GROUP Rises 3.25% in Regular Trading, Multiple New Drug Approvals and Pipeline Milestones Drive Momentum

Market Focus
·
Aug 07

Sino Biopharm Unit Gets Marketing Nod for Anti-Inflammatory Analgesic in China

MT Newswires Live
·
Aug 06

Sino Biopharm (SBP Group) Secures NMPA Green Light and Four-Year Data Protection for Second-Generation Flurbiprofen Patch

Bulletin Express
·
Aug 06

Sino Biopharmaceutical - Second-Generation Flurbiprofen Patch Approved for Marketing

THOMSON REUTERS
·
Aug 06

Sino Biopharmaceutical to Review 1H26 Results and Potential Interim Dividend on 19 August 2026

Bulletin Express
·
Aug 06

Sino Biopharma Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 06

Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong

Dow Jones
·
Aug 05

Sino Biopharma Unit's Application for Lymphocytic Leukemia Drug Accepted in China

MT Newswires Live
·
Aug 04

Sino Biopharma Says China CDE Accepts NDA for Tqb3909 BCL-2 Inhibitor in Cll/sll

Reuters
·
Aug 04

Sino Biopharmaceutical - New Drug Application for Tqb3909 Tablet Accepted by China's Cde

THOMSON REUTERS
·
Aug 04

Sino Biopharma Unit Gets Breakthrough Therapy Designation for Cancer Drug in China

MT Newswires Live
·
Aug 03

SBP Group's Third Breakthrough Therapy Designation for TQB2102 Strengthens Its Position in HER2-Targeted Cancer Treatments

Stock News
·
Aug 03

Sino Biopharmaceutical - Tqb2102 Her2 Bispecific ADC Granted Breakthrough Therapy Designation by Cde for Her2-Low Breast Cancer

THOMSON REUTERS
·
Aug 03

Sino Biopharmaceutical Stock Falls 1.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 03

SBP GROUP to Present 21 Oncology Studies—Five as Oral Sessions—at 2026 CSCO Annual Meeting

Bulletin Express
·
Jul 30

SBP Group Unveils 21 Studies for Upcoming Oncology Conference, Including 5 Oral Presentations

Stock News
·
Jul 30

Stock Track | SBP GROUP Plummets 5.35% Intraday as Pharmaceutical Sector Faces Broad Selling Pressure

Stock Track
·
Jul 30